Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?
unknown
📅 Published: 2026-03-06 12:39
📰 Source: Yahoo
📝 Words: 25
📝 Article Content
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA review.
📄 Summary
ABBV's neuroscience unit delivered $10.8B in 2025 and can hit $12.5B in 2026 as Vyalev gains traction and new Parkinson's drug tavapadon awaits FDA review.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-13 18:10:42
Updated At:
2026-03-13 18:10:42
Scraping Job ID:
N/A
Stock Mentions:
ABBV - AbbVie Inc.
Relevance: N/A